Efficacy Subgroup Analyses

Jay N. Cohn, MD
Professor of Medicine
University of Minnesota Medical School
Val-HeFT Study Chairman

NOVARTIS

Morbidity by Baseline Demographics (Val-HeFT)



Morbidity by Baseline Disease Characteristics (Val-HeFT)



NOVARTIS

Mortality by ACE Inhibitor/Beta-blocker Subgroups (Val-HeFT)



Morbidity by ACE Inhibitor/Beta-blocker Subgroups (Val-HeFT)



Morbidity in Cotherapy Groups and Subgroups at Baseline (Val-HeFT)

	Valsartan N = 2,511	Placebo N = 2,499	Morbidity, %		Hazard ratio§	95% CI	Log-rank *P* value
			Val	Plc			
Groups							
ACEI (yes)	2,326	2,318	29.1	31.2	0.901	(0.812, 1.001)	.096
ACEI (no)	185	181	24.9	42.5	0.560	(0.385, 0.813)	.0002*
BB (yes)	867	883	25.0	22.9	1.112	(0.917, 1.347)	.343
BB (no)	1,644	1,616	30.8	37.1	0.794	(0.705, 0.894)	.0001*
Subgroups							
ACEI (no), BB (no)	112	114	27.7	47.4	0.561	(0.357, 0.879)	.003*
ACEI (yes), BB (no)	1,532	1,502	31.0	36.3	0.817	(0.722, 0.924)	.002*
ACEI (no), BB (yes)	73	67	20.5	34.3	0.578	(0.294, 1.137)	.037*
ACEI (yes), BB (yes)	794	816	25.4	21.9	1.185	(0.969, 1.450)	.104
All except ACEI (yes), BB (yes)	1,717	1,683	30.3	37.0	0.785	(0.698, 0.882)	.00003*

*$P < .05$.
§Cox regression.

NOVARTIS

Patients on Cotherapy at Endpoint (Val-HeFT)

	Valsartan				Placebo			
	N at BL	% at end-point	N not at BL	% started during trial	N at BL	% at end-point	N not at BL	% started during trial
ACE inhibitors	2,326	90.3	185	16.3	2,318	93.5	181	16.7
Beta-blockers	867	92.3	1,644	13.0	883	92.0	1,616	16.5
Diuretics	2,154	94.6	357	31.4	2,128	96.0	371	31.3
Nitrates§	986	86.5	1,525	10.0	957	86.7	1,542	12.6
Spironolactone	124	65.9	2,387	8.1	126	75.4	2,373	12.5

§Includes both long- and short-acting nitrates.

Mortality of Patients Not on ACE Inhibitors (Val-HeFT)



Patients at risk

Months	0	6	12	18	24	30
Valsartan	185	177	168	131	100	48
Placebo	181	165	160	122	76	35

P value (log-rank): 0.0171
Hazard ratio (Cox model): 0.6694

NOVARTIS

Morbidity of Patients Not on ACE Inhibitors (Val-HeFT)



Patients at risk

Months	0	6	12	18	24	30
Valsartan	185	168	159	120	85	44
Placebo	181	148	132	99	58	34

P value (log-rank) = .0002
Hazard ratio (Cox model): 0.560

NOVARTIS

Left Ventricular Ejection Fraction LSM Change From Baseline at Endpoint by Cotherapy Subgroup (Val-HeFT)



*$P < .05$.

NOVARTIS

LVEF by ACE Inhibitor/Beta-blocker Subgroups Least Square Mean Change from Baseline at Endpoint (Val-HeFT)



*Statistically significant at $P < .05$.

NOVARTIS

Left Ventricular Internal Diastolic Diameter Adjusted for BSA at Endpoint—LSM Change From Baseline by Cotherapy Subgroup (Val-HeFT)



*Statistically significant.

NOVARTIS

LVIDD by ACE Inhibitor/Beta-blocker Subgroups Least Square Mean Change from Baseline at Endpoint (Val-HeFT)



A (Y)	B (Y)	All subgroups except A (Y)	All subgroups except B (Y)	Overall A (Y)	Overall B (Y)
733	776	1,561	1,555	2,294	2,331

*Statistically significant at $P < .05$.

NOVARTIS

LSM Change in Minnesota LHFQ Overall Score by Baseline Cotherapy Subgroups at Endpoint (Val-HeFT)



*Statistically significant at $P < .05$.

QOL Overall by ACE Inhibitor/ Beta-blocker Subgroups Least Square Mean Change from Baseline at Endpoint (Val-HeFT)



*Statistically significant at $P < .05$.

NOVARTIS

NYHA Class by ACE Inhibitor/Beta-blocker Subgroups at Endpoint (Val-HeFT)



*Statistically significant at $P < .05$.

NOVARTIS

Mortality by ACE Inhibitor/Beta-blocker Subgroups (Val-HeFT)



Morbidity by ACE Inhibitor/Beta-blocker Subgroups (Val-HeFT)



Val-HeFT: Summary of Results

- Benefit on morbidity was seen in patients using ACE inhibitors or beta-blockers, but not both